Table 1 Characteristics of the de novo patient study cohort (n = 28)
Characteristic | Value |
|---|---|
Age at diagnosis, years | 49.07 ± 17.94 |
Sex, no. (%) | |
 Male | 11 (39) |
 Female | 17 (61) |
 Bone marrow blast, no. (%) | 67.55 ± 23.74 |
AML FAB subtype, no. (%) | |
 M1 | 1 (3.57) |
 M2 | 5 (17.86) |
 M4 | 10 (35.71) |
 M5 | 11 (39.29) |
 M6 | 1 (3.57) |
2017 NCCN cytogenetic risk classification, no. (%) | |
 Good | 5 (17.86) |
 Intermediate | 20 (71.43) |
 Poor | 3 (10.71) |
2017 NCCN molecular risk classification, no. (%) | |
 Good | 12 (42.86) |
 Intermediate | 7 (25.00) |
 Poor | 9 (32.14) |
Mutation, no. (%) | |
 t(8;21) | 3 (10.71) |
 inv(16) | 2 (7.14) |
 NPM1 | 4 (14.29) |
 FLT3 | 6 (21.43) |
 DNMT3A | 3 (10.71) |
 IDH1 or IDH2 | 4 (14.29) |
 KRAS or NRAS | 4 (14.29) |
 TP53 | 2 (7.14) |
 biCEBPA | 7 (25.00) |